Suzanne Kabzinski
Family Medicine · Conroe, TXNPI 1720403066
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 429 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$803
- AstraZeneca$414
- Novo Nordisk$395
- GSK$351
- Pfizer$342
- plus $4K from 42 others
What the payments were for
- Food & beverage$7,14099%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,239 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 48 | $67,939 |
| OzempicSemaglutide | 27 | $29,769 |
| EliquisApixaban | 18 | $28,249 |
| JardianceEmpagliflozin | 17 | $17,864 |
| XareltoRivaroxaban | 13 | $10,176 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $8,695 |
| Armour ThyroidThyroid,pork | 34 | $2,268 |
| SynthroidLevothyroxine Sodium | 18 | $2,169 |
| Trazodone Hcl | 31 | $1,159 |
| Sertraline Hcl | 36 | $1,120 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 11 | $986 |
| Liothyronine Sodium | 21 | $984 |
| ProgesteroneProgesterone, Micronized | 16 | $844 |
| Testosterone Cypionate | 13 | $761 |
| Temazepam | 55 | $757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $803 | $67,93948 claims |
| Novo NordiskOzempic | $395 | $29,76927 claims |
| PfizerEliquis | $342 | $28,24918 claims |
| Boehringer IngelheimJardiance | $110 | $17,86417 claims |
| Johnson & JohnsonXarelto | $13 | $10,17613 claims |
| GSKTrelegy Ellipta | $351 | $8,69516 claims |
| AbbVieArmour Thyroid, Synthroid | $1,271 | $4,43752 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $102 | $58816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Conroe
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.